(Press-News.org) This news release is available in French.
A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression. These encouraging results from in vitro tests in humans and in vivo tests in mice were published today in the Annals of Neurology. "We believe we have identified the first therapy that will impact the quality of life of people with multiple sclerosis by significantly reducing the disability and the disease's progression," said Dr. Alexandre Prat, lead author of the study, researcher at the CRCHUM, and professor in the Department of Neurosciences at the University of Montreal.
Multiple sclerosis (MS) is a neurological disease that is characterized by paralysis, numbness, loss of vision, and gait and balance deficits that lead to chronic disability. There is no effective cure. The disease particularly affects young adults in northern countries. In Canada, nearly 75,000 people have MS.
The brain is normally protected from attacks by the blood-brain barrier. The blood-brain barrier prevents immune cells - lymphocytes - from entering the central nervous system. In people with MS, there is often leakage. Two types of lymphocytes, CD4 and CD8, find a way to cross this protective barrier. They attack the brain by destroying the myelin sheath that protects neurons, resulting in decreased transmission of nerve impulses, and plaque formation.
In 2008, Dr. Prat's team identified a cell adhesion molecule, called MCAM (Melanoma Cell Adhesion Molecule), which plays a crucial role in dysregulation of the immune system observed in multiple sclerosis. "Our studies have shown that MCAM is necessary for the migration of CD4 and CD8 across the blood-brain barrier. If we block the interaction of MCAM with the protein to which it normally binds, we decrease the disease's activity," he said. Independently, the biotechnology company Prothena Corporation plc also discovered complementary data regarding MCAM, which led to an ongoing collaboration between the CRCHUM and Prothena.
The results are extremely positive. "We observed a decrease of approximately 50% of the disease in mice with experimental autoimmune encephalomyelitis (EAE), the most widely used animal model of MS. What is especially significant is that we can stop the disease from the first symptoms in addition to having an impact on its progression, which is a first," noted Prat.
MS develops in most patients in two phases. For 10 to 15 years, there are outbreaks of symptoms interspersed with remissions. Later, the diseases progresses and the disability worsens, leading to the use of a cane or wheelchair. Currently, none of the drugs available on the market affect the disease's progression.
Prothena has developed a potentially disease-modifying antibody, called PRX003, which is designed, to inhibit MCAM function and thus prevent migration of destructive lymphocytes into tissue. Prothena expects to initiate clinical trials of PRX003 in healthy volunteers by the end of June, and anticipates a study in patients with psoriasis in 2016. Beyond psoriasis, anti-MCAM antibodies may be useful for treating a variety of diseases, including progressive forms of multiple sclerosis.
INFORMATION:
About the study
The study was funded by the Canadian Institutes of Health Research (CIHR), the Multiple Sclerosis Society of Canada, and the Fonds de recherche du Québec - Santé (FRQS). Alexandre Prat holds the Canada Research Chair in Multiple Sclerosis. At the CRCHUM, Alexandre Prat, Hania Kebir, and Nathalie Arbour hold a patent on MCAM. At Prothena Corporation plc, Ken Flanagan and Ted Yednock have a patent pending on treatments with MCAM antagonists. The University of Montreal is officially known as Université de Montréal. For more information, see the article abstract in the Annals of Neurology: http://onlinelibrary.wiley.com/doi/10.1002/ana.24415/abstract
Women with advanced ovarian cancer have fewer side effects and tend to have a better quality of life if given chemotherapy before surgery, according to a Cancer Research UK study published today (Wednesday) in The Lancet.
The CHORUS trial, conducted at the Medical Research Council Clinical Trials Unit at University College London, challenged the international standard for treating advanced ovarian cancer.
550 women with the disease took part in the trial, with 276 given the standard treatment of surgery followed by six cycles of chemotherapy, and 274 had surgery after ...
Researchers at the University of Birmingham have highlighted significant similarities between the behavioural effects of oxytocin and alcohol.
The research, published today in Neuroscience and Biobehavioral Reviews, draws on existing studies into the two compounds and details the similarities between the effects of alcohol and the 'love hormone', oxytocin, on our actions. The team warn that the oft-used nickname hides the darker side of oxytocin, and claim that it bears more semblances with the effects of alcohol than previously thought.
Oxytocin is a neuropeptide ...
Cold-blooded and other animals that are unable to regulate their internal temperature may have a hard time tolerating global warming, according to an analysis by biologists from the University of California, Berkeley, and San Francisco State University.
A meta-analysis of studies that measured the ability of animals to deal with extremes of heat and cold found that, on average, most ectotherms are not very flexible. Terrestrial ectotherms, such as lizards and insects, are even less adaptable than fish and crustaceans, they found.
As Earth warms, these animals will be ...
The proportion of people dying in hospices in England has nearly doubled since 1993, but the gap in hospice deaths between people living in the least and most deprived areas appears to be growing, find a new study by the Cicely Saunders Institute at King's College London.
The study, funded by the National Institute for Health Research HS&DR Programme (09/2000/58) through the NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) and published in the journal Palliative Medicine, examined all hospice deaths in England over a 20-year period, including ...
A new study published in the journal Proceedings of the Royal Society B by the teams of Dr. Gregory West (Assistant Professor at the Université de Montréal) and Dr. Véronique Bohbot (Douglas Institute researcher and associate Professor at McGill University and the Douglas Research Institute of the CIUSSS de l'Ouest-de-l'Île de Montréal) shows that while video game players (VGPs) exhibit more efficient visual attention abilities, they are also much more likely to use navigation strategies that rely on the brain's reward system (the caudate nucleus) ...
ATS 2015, DENVER--Patient-selected music during weaning from prolonged mechanical ventilation could benefit patients by decreasing their heart rate and anxiety, according to a study presented at the 2015 American Thoracic Society International Conference.
Patients on prolonged mechanical ventilation may feel stress or insecurity during daily weaning trials because they do not have support from the ventilator. "Having patients listen to music during these trials may help reduce stress and speed up extubation," said lead author Zhan Liang, a PhD candidate at the University ...
ATS 2015, DENVER -- Critically ill patients who have been mechanically ventilated for more than seven days are at greatly increased risk for functional impairment and mortality at one year following discharge from the intensive care unit (ICU), according to a new study presented at the 2015 American Thoracic Society International Conference.
"Prolonged mechanical ventilation has a significant impact on the long-term well-being of patients," said lead author Margaret Herridge. MD, MPH. of the University of Toronto. "In our study of nearly 400 ICU patients, we were able ...
DARIEN, IL - A new study of young U.S. veterans shows that the probability of having a high risk of obstructive sleep apnea (OSA) increased with increasing severity of post-traumatic stress disorder (PTSD) symptoms.
The study involved 195 Iraq and Afghanistan veterans who visited a VA outpatient PTSD clinic for evaluation. Results show that 69.2 percent of participants had a high risk for sleep apnea, and this risk increased with PTSD symptom severity. Every clinically significant increase in PTSD symptom severity was associated with a 40 percent increase in the probability ...
WASHINGTON, D.C., May 19, 2015 -- Playing natural sounds such as flowing water in offices could boosts worker moods and improve cognitive abilities in addition to providing speech privacy, according to a new study from researchers at Rensselaer Polytechnic Institute. They will present the results of their experiment at the 169th Meeting of the Acoustical Society of America, held May 18-22, 2015 in Pittsburgh.
An increasing number of modern open-plan offices employ sound masking systems that raise the background sound of a room so that speech is rendered unintelligible ...
Children born since the 1980s are two to three times more likely than older generations to be overweight or obese by the age of 10, according to new research published in PLOS Medicine. The study, conducted by researchers from CLOSER, a consortium of UK longitudinal studies, characterized population shifts in body mass index (BMI) using data from more than 56,000 people born in Britain from 1946 to 2001.
The findings will be relevant to policymakers and health care professionals, who predict the obesity epidemic will cost the UK's National Health Service (NHS) £22.9 ...
